Eric Reed Lazear

Title: Eric Reed Lazear: Innovator in Targeted Cytokine Delivery

Introduction

Eric Reed Lazear is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of immunotherapy, holding a total of 4 patents. His work focuses on enhancing the effectiveness of immunotherapy while minimizing its side effects.

Latest Patents

Lazear's latest patents include innovative compositions and methods for targeted cytokine delivery. One of his key disclosures encompasses compositions that link a cytokine to an NKG2D ligand or PD1 ligand. This approach aims to improve immunotherapy by limiting the side effects typically associated with such treatments. Additionally, he has developed methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. These compositions are designed to enhance the efficacy of immunotherapy while reducing adverse effects.

Career Highlights

Throughout his career, Lazear has worked with prestigious institutions, including Washington University. His research has significantly advanced the understanding and application of targeted therapies in immunology.

Collaborations

Lazear has collaborated with notable colleagues such as Alexander Sasha Krupnick and Daved Henry Fremont. Their joint efforts have contributed to the development of innovative solutions in the field of immunotherapy.

Conclusion

Eric Reed Lazear's work in targeted cytokine delivery represents a significant advancement in immunotherapy. His innovative approaches aim to improve treatment outcomes while minimizing side effects, showcasing his commitment to enhancing patient care.